Patents by Inventor Didier Scherrer
Didier Scherrer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11826372Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.Type: GrantFiled: December 6, 2021Date of Patent: November 28, 2023Assignee: ABIVAXInventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
-
Patent number: 11739073Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.Type: GrantFiled: July 9, 2019Date of Patent: August 29, 2023Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau-Betzer, Romain Najman, Julien Santo, Cécile Apolit
-
Patent number: 11649210Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:Type: GrantFiled: August 17, 2020Date of Patent: May 16, 2023Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman
-
Patent number: 11649211Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:Type: GrantFiled: December 7, 2020Date of Patent: May 16, 2023Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
-
Publication number: 20230142547Abstract: The treatment or prevention of a Coronaviridae infection, and conditions related thereto; in particular a Coronaviridae infection in humans. In particular, the compounds, pharmaceutical compositions and medicaments for treating and/or preventing a Coronaviridae infection and/or its long-term consequences. The uses and methods for assessing a Coronaviridae infection or the efficacy of a treatment of such infections.Type: ApplicationFiled: March 19, 2021Publication date: May 11, 2023Applicant: ABIVAXInventors: Jamal TAZI, Hartmut EHRLICH, Philippe POULETTY, Julien SANTO, Didier SCHERRER
-
Publication number: 20230106420Abstract: A compound of formula (I) is: wherein: X2 represents a —CO—NRk— group, a —NR?k—CO— group, a —O— group, a —CO— group, a —SO2-group, a —CS—NH— group, a —CH2—NH—, a group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C5-C11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C1-C4)alkenyl group, a —PO(ORa)(ORb) group, a 5-membered heteroaromatic ring or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.Type: ApplicationFiled: July 17, 2020Publication date: April 6, 2023Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Florence MAHUTEAU, Romain NAJMAN, Jamal TAZI, Julien SANTO, Cécile APOLIT, Frederic LABEGUERE, Brice SAUTIER, Natacha BIENVENU, Elisa AZZALI
-
Publication number: 20220356175Abstract: A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.Type: ApplicationFiled: July 9, 2019Publication date: November 10, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Publication number: 20220315535Abstract: In vitro or ex vivo methods for screening a quinoline derivative, or anyone of its pharmaceutically acceptable salt, presumed effective in treating and/or preventing an inflammatory disease, the method including: providing an eukaryotic cell, bringing into contact said cell with a quinoline derivative, measuring an expression of miR-124 in the cell, and selecting the candidate presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured is increased relatively to a reference value.Type: ApplicationFiled: May 17, 2022Publication date: October 6, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier SCHERRER, Jamal TAZI
-
Patent number: 11441181Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.Type: GrantFiled: January 17, 2014Date of Patent: September 13, 2022Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jamal Tazi, Didier Scherrer, Aude Garcel, Noëlie Campos, Romain Najman, Florence Mahuteau-Betzer
-
Patent number: 11427566Abstract: A compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.Type: GrantFiled: April 15, 2020Date of Patent: August 30, 2022Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
-
Publication number: 20220193089Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.Type: ApplicationFiled: December 6, 2021Publication date: June 23, 2022Applicant: ABIVAXInventors: Sandrine CRABE, Didier SCHERRER, Hartmut EHRLICH, Philippe POULETTY
-
Publication number: 20220145406Abstract: Biomarkers and uses thereof in monitoring, assessing, and/or treatment of viral infections, or inflammatory diseases, disorders, or conditions, or cancer.Type: ApplicationFiled: December 19, 2019Publication date: May 12, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITÉ DE MONTPELLIERInventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI, Laurent MANCHON
-
Publication number: 20220127253Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.Type: ApplicationFiled: May 21, 2021Publication date: April 28, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal TAZI, Florence MAHUTEAU, Pierre ROUX, Romain NAJMAN, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC, Gilles GADEA, Noelie CAMPOS, Aude GARCEL, Julien SANTO
-
Patent number: 11278552Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.Type: GrantFiled: September 14, 2017Date of Patent: March 22, 2022Assignee: AbivaxInventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
-
Publication number: 20220071985Abstract: A compound of formula (Ib?) or anyone of its metabolites or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia wherein R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1 R2, —SO3H, —O— SO2—OR3, —O—P(?O)(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl, said alkyl being optionally mono- or di-substituted by a hydroxyl group, a -A-(CH2)m—B—NRaRb group, or a —(O—CH2—CH2)p—O—Ra group. The present disclosure also relates to a compound of formula (IVb?) or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia.Type: ApplicationFiled: December 19, 2019Publication date: March 10, 2022Applicants: ABIVAX, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI
-
Patent number: 11266667Abstract: The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.Type: GrantFiled: September 13, 2018Date of Patent: March 8, 2022Assignee: ABIVAXInventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
-
Publication number: 20220023324Abstract: A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(?O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R? is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(?O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R?, n, and n? are as described above.Type: ApplicationFiled: December 19, 2019Publication date: January 27, 2022Applicants: ABIVAX, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI
-
Publication number: 20210309611Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.Type: ApplicationFiled: July 9, 2019Publication date: October 7, 2021Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Publication number: 20210300871Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.Type: ApplicationFiled: July 9, 2019Publication date: September 30, 2021Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Patent number: 11014918Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.Type: GrantFiled: February 11, 2020Date of Patent: May 25, 2021Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Julien Santo